香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 WinHealth International Holding Group Company Limited 維健國際控股集團有限公司 （「本公司」） （於英屬維爾京群島註冊成立的有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件，即代 表您知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》與香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請， 準投資者務請僅依據呈交香港公司註冊處註冊的本公司招股章程作出投資決定；有關文本將於 發售期內向公眾刊發。 (a) 本文 ...

Core Viewpoint - The article discusses the emergence of Demy Pharmaceutical, a subsidiary of Kangzhe Pharmaceutical, focusing on the development and market potential of the drug "Ruxolitinib Cream" for treating vitiligo, amidst a growing demand for effective skin health products in China [1][2]. Company Overview - Demy Pharmaceutical is set to independently list in Hong Kong, having submitted its prospectus in April 2023, and is positioned to capitalize on the skin health market, which is projected to be worth billions [1][2]. - The company has a strong product pipeline, including Ruxolitinib Cream, which is the only FDA-approved JAK inhibitor for vitiligo, and other skin-related products [3][5]. Market Potential - There are over 10 million vitiligo patients in China, and the market for effective treatments is largely untapped, with Ruxolitinib Cream expected to generate significant revenue, projected at $340 million in its first full sales year [4][10]. - The skin health market is characterized by a high demand for unique and effective treatments, with Demy focusing on products that have a strong market need and limited competition [7][11]. Financial Performance - Demy Pharmaceutical has shown promising financials, with revenues expected to exceed 600 million yuan in 2024, reflecting a growth trend in the skin health segment [2][7]. - The company has maintained a positive cash flow despite not yet being profitable, indicating strong market interest and potential for future growth [2][10]. Product Pipeline - The product pipeline includes several other skin prescription drugs, with a focus on unique and differentiated products that address significant medical needs [5][7]. - The company has successfully introduced products that are the only approved treatments for specific conditions in China, enhancing its competitive edge [7][11]. Sales Strategy - Demy Pharmaceutical's sales strategy emphasizes leveraging its parent company's marketing expertise and established distribution channels, with a focus on hospital and retail pharmacy coverage [10][12]. - The company has a strong commercial team, with over 85% of its workforce dedicated to sales, which is crucial for its growth in the competitive biopharmaceutical market [10][12].